Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kathleen Haden
Observed names:
K Haden,
Kathleen R. Haden
Institutions:
University of Virginia Health System,
University of Virginia Medical Center,
University of Virginia
Observed institutions:
University of Virginia Health System,
University of Virginia Medical Center,
University of Virginia Cancer Center,
University of Virginia
ORCID:
0009-0003-2467-160X
Observed ORCID:
0009-0003-2467-160X
OpenAlex ID:
A5138812648
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma
2020
·
Victor H Engelhard
, Rebecca C Obeng
, et al.
·
Journal for ImmunoTherapy of Cancer
·
92
PDF
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
2021
·
Sapna P Patel
, Gina R Petroni
, et al.
·
Journal for ImmunoTherapy of Cancer
·
61
PDF
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
2022
·
Rick D Vavolizza
, Gina R Petroni
, et al.
·
Journal for ImmunoTherapy of Cancer
·
46
PDF
Men’s attitudes regarding genetic testing for hereditary prostate cancer risk
2000
·
Susan Miesfeldt
, Susan M Jones
, et al.
·
Urology
·
37
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)
2021
·
Craig L Slingluff, Jr.
, Gina R Petroni
, et al.
·
Journal for ImmunoTherapy of Cancer
·
28
PDF
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)
2026
·
Emily K Ninmer
, Gina R Petroni
, et al.
·
Journal for ImmunoTherapy of Cancer
·
6
PDF
1466 Phase I/II clinical trial of a melanoma vaccine targeting shared nonmutated antigens and a shared mutated neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR agonist (polyICLC)
2024
·
Emily K Ninmer
, Gina R Petroni
, et al.
·
Journal for ImmunoTherapy of Cancer
·
3
Survival benefit associated with screening of patients at elevated risk for pancreatic cancer
2024
·
William J. Kane
, Kathleen R. Haden
, et al.
·
Journal of Surgical Oncology
·
3
Characterization of driver oncogenic mutations of in-transit melanoma metastases.
2024
·
Mohamad El Moheb
, Susan Kim
, et al.
·
Journal of Clinical Oncology
·
2
388 A trial to evaluate the safety, immunogenicity, and clinical activity of a helper peptide vaccine plus PD-1 blockade (Mel64, PATHVACS: PD-1 antibody and T-helper vaccine and correlative studies)
2021
·
Craig Slingluff
, Kimberly Chianese-Bullock
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
Breast cancer prevention with tamoxifen.
2000
·
K Haden
, R Santen
·
PubMed
·
1
Table 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S3 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S6 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Figure S1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S2 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Supplementary File 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S4 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S10 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Data from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Figure S2 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Figure 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Figure 4 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Table S8 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
2026
·
Emily K. Ninmer
, Gina R. Petroni
, et al.
Show more works
View as search
Works count:
36
Citation count:
281
H-index:
6
I10-index:
5
Year
Topic
Type